» Articles » PMID: 37840917

Exploring the Causes of Augmentation in Restless Legs Syndrome

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Oct 16
PMID 37840917
Authors
Affiliations
Soon will be listed here.
Abstract

Long-term drug treatment for Restless Legs Syndrome (RLS) patients can frequently result in augmentation, which is the deterioration of symptoms with an increased drug dose. The cause of augmentation, especially derived from dopamine therapy, remains elusive. Here, we review recent research and clinical progress on the possible mechanism underlying RLS augmentation. Dysfunction of the dopamine system highly possibly plays a role in the development of RLS augmentation, as dopamine agonists improve desensitization of dopamine receptors, disturb receptor interactions within or outside the dopamine receptor family, and interfere with the natural regulation of dopamine synthesis and release in the neural system. Iron deficiency is also indicated to contribute to RLS augmentation, as low iron levels can affect the function of the dopamine system. Furthermore, genetic risk factors, such as variations in the and genes, have been linked to an increased risk of RLS initiation and augmentation. Additionally, circadian rhythm, which controls the sleep-wake cycle, may also contribute to the worsening of RLS symptoms and the development of augmentation. Recently, Vitamin D deficiency has been suggested to be involved in RLS augmentation. Based on these findings, we propose that the progressive reduction of selective receptors, influenced by various pathological factors, reverses the overcompensation of the dopamine intensity promoted by short-term, low-dose dopaminergic therapy in the development of augmentation. More research is needed to uncover a deeper understanding of the mechanisms underlying the RLS symptom and to develop effective RLS augmentation treatments.

Citing Articles

Suspected duloxetine-induced restless legs syndrome phenotypic variant: a case report.

Shao Y, Chen Y, Wang S, Li C, Sun H, Sun X BMC Psychiatry. 2024; 24(1):349.

PMID: 38730422 PMC: 11088019. DOI: 10.1186/s12888-024-05763-7.

References
1.
Rudisill S, Martin B, Mankowski K, Tessier C . Iron Deficiency Reduces Synapse Formation in the Drosophila Clock Circuit. Biol Trace Elem Res. 2018; 189(1):241-250. PMC: 6338522. DOI: 10.1007/s12011-018-1442-7. View

2.
Trenkwalder C, Paulus W . Pharmacological treatments of augmentation in restless legs syndrome patients. Adv Pharmacol. 2019; 84:255-265. DOI: 10.1016/bs.apha.2019.02.002. View

3.
Manconi M, Garcia-Borreguero D, Schormair B, Videnovic A, Berger K, Ferri R . Restless legs syndrome. Nat Rev Dis Primers. 2021; 7(1):80. DOI: 10.1038/s41572-021-00311-z. View

4.
Montplaisir J, Karrasch J, Haan J, Volc D . Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord. 2006; 21(10):1627-35. DOI: 10.1002/mds.21050. View

5.
Garcia-Borreguero D, Larrosa O, Granizo J, de la Llave Y, Hening W . Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Sleep. 2004; 27(4):669-73. View